Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has issued an update.
On February 20, 2026, Eupraxia Pharmaceuticals announced it had closed a US$63.2 million public offering of 7,607,145 common shares and 1,428,571 pre-funded warrants, including full exercise of the underwriters’ option, at prices of US$7.00 per share and US$6.99999 per warrant. Cantor and LifeSci Capital led the deal, with Bloom Burton and Craig-Hallum as co-managers, under a cross-border prospectus structure using a U.S. Form F-10 and a Canadian base shelf.
The company plans to use the proceeds primarily to advance its lead candidate EP-104GI for eosinophilic esophagitis through preclinical work, Phase 2 trials, Phase 3 preparation, manufacturing, and commercial planning. Funds are also earmarked to expand EP-104GI into additional gastrointestinal indications such as esophageal strictures and fibrostenotic Crohn’s disease, support new pipeline research, business development, intellectual property, and broader corporate infrastructure, bolstering Eupraxia’s growth trajectory and readiness for eventual product launch.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn), partially offset by a conservatively levered balance sheet. Technicals are the main positive, showing a clear uptrend and constructive momentum, while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing locally delivered, extended-release drug products for therapeutic areas with high unmet medical need. Its proprietary Diffusphere polymer-based microsphere technology is designed to enable targeted, controlled delivery of both existing and novel drugs, with current work centered on gastrointestinal indications.
Average Trading Volume: 78,309
Technical Sentiment Signal: Buy
Current Market Cap: C$571.5M
For detailed information about EPRX stock, go to TipRanks’ Stock Analysis page.